Patel AN, Wu SS, Colevas AD, Divi V, et al. Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs. Oral Oncol 2026;182:108125.
PMID: 42766895